Patents by Inventor Antoine Deslandes

Antoine Deslandes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20190284294
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 19, 2019
    Inventors: Antoine DESLANDES, Krzysztof J. GRZEGORZEWSKI, Marie-Laure OZOUX, Blake TOMKINSON
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20180022814
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 25, 2018
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS
    Publication number: 20150118251
    Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 30, 2015
    Inventors: Antoine Deslandes, Krzysztof J. Grzegorzewski, Marie-Laure Ozoux, Blake Tomkinson
  • Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies
    Patent number: 6599896
    Abstract: The invention relates to the use of tianeptine or enantiomers thereof in obtaining medicaments for use in the treatment of neurodegenerative pathologies.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: July 29, 2003
    Assignee: Les Laboratoires Servier
    Inventors: Antoine Deslandes, Michael Spedding